Cisplatin (≥0.5 mg/ml)

Cisplatina (≥0,5 mg/mL)Cisplatino (≥0,5 mg/ml)

References

Risk class: VesicantONS/ASCO 2025 (Table 1, p. 385)

Antidote: sodium thiosulfateONS/ASCO 2025 (Table 4, p. 391)

Compress: coldONS/ASCO 2025 (text, p. 390)

Not classified in: ESMO-EONS 2012, JSCN/JSMO/JASPO 2024

Not classified in: ESMO-EONS 2012, JSCN/JSMO/JASPO 2024

ONS/ASCO 2025Sodium thiosulfate
"greater than 20 ml" extravasatedcisplatin in high concentration (greater than 0.5 mg/ml)
Table 4, p. 391

ONS/ASCO 2025Cold compress
Strength/level: Conditional; very lowAlkylating agents per ONS/ASCO Table 1; oxaliplatin excluded because the same guideline indicates a warm compressalkylating agents, anthracyclines, and antimetabolites
text, p. 390

Brand names (ANVISA, Brazil) · DCB (Brazil)

DCB (Brazil)cisplatina (nº 2156)

Brand names (ANVISA, Brazil)C-PLATIN, CITOPLAX, FAULDCISPLA, MYLLCIS

General recommendations of the guidelines

ONS/ASCO 2025Recommendation 1 · Strong; very low
Use antidotes, when one exists, for vesicants and irritants with vesicant properties, rather than no antidote.
Table 3, p. 388
ONS/ASCO 2025Recommendation 3 · Conditional; very low
Thermal compress (cold or warm depending on the agent) rather than no compress.
Table 3, p. 388
ONS/ASCO 2025Recommendation 4 · Conditional; very low
Compress for more than 24 hours rather than 24 hours or less.
Table 3, p. 388
ONS/ASCO 2025Recommendation 5 · Conditional; very low
Central line extravasation: surgical referral or escalation of care in addition to conservative management.
Table 3, p. 388
JSCN/JSMO/JASPO 2024CQ10a · Recommend (weak)
Cold compression (weak recommendation).
Table 1, CQ10a
JSCN/JSMO/JASPO 2024CQ10b · Not recommend (weak); D
Non-use of warm compresses (weak recommendation).
Table 1, CQ10b